Nasopharyngeal SARS-CoV-2 load and perinatal outcomes after maternal infection diagnosed close to delivery.
Asphyxia
Birth weight
COVID-19
NICU
Neonate
Pregnancy
Prematurity
Journal
Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
31
01
2023
revised:
26
02
2023
accepted:
01
03
2023
medline:
25
4
2023
pubmed:
7
3
2023
entrez:
6
3
2023
Statut:
ppublish
Résumé
The occurrence of COVID-19 during the pregnancy can cause several negative maternal and neonatal outcomes. Nasopharyngeal viral load is associated with inflammatory markers and might influence the disease severity in non-pregnant patients, but there are no data about the relationship between viral load and perinatal outcomes in pregnant patients. To investigate the hypothesis that nasopharyngeal SARS-CoV-2 load (estimated with real-time polymerase chain reaction delta cycle (ΔCt), measured in hospital clinical laboratories) is associated with perinatal outcomes, when COVID-19 is diagnosed in the third trimester of pregnancy. International, retrospective, observational, multi-center, cohort study enrolling 390 women (393 neonates, three pairs of twins), analyzed with multivariate generalized linear models with skewed distributions (gamma) and identity link. The analyses were conducted for the whole population and then followed by a subgroup analysis according to the clinical severity of maternal COVID-19. The estimated viral load in maternal nasopharynx is not significantly associated with gestational age at birth (adjusted B: -0.008 (95%CI: -0.04; 0.02); p = 0.889), birth weight (adjusted B: 4.29 (95%CI: -25; 35); p = 0.889), weight Z-score (adjusted B: -0.01 (95%CI: -0.03; 1); p = 0.336), 5' Apgar scores (adjusted B: -0. -9.8e The estimated maternal nasopharyngeal viral load in pregnant women affected by COVID-19 during the third trimester is not associated with main perinatal outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
The occurrence of COVID-19 during the pregnancy can cause several negative maternal and neonatal outcomes. Nasopharyngeal viral load is associated with inflammatory markers and might influence the disease severity in non-pregnant patients, but there are no data about the relationship between viral load and perinatal outcomes in pregnant patients.
OBJECTIVE
OBJECTIVE
To investigate the hypothesis that nasopharyngeal SARS-CoV-2 load (estimated with real-time polymerase chain reaction delta cycle (ΔCt), measured in hospital clinical laboratories) is associated with perinatal outcomes, when COVID-19 is diagnosed in the third trimester of pregnancy.
STUDY DESIGN
METHODS
International, retrospective, observational, multi-center, cohort study enrolling 390 women (393 neonates, three pairs of twins), analyzed with multivariate generalized linear models with skewed distributions (gamma) and identity link. The analyses were conducted for the whole population and then followed by a subgroup analysis according to the clinical severity of maternal COVID-19.
RESULTS
RESULTS
The estimated viral load in maternal nasopharynx is not significantly associated with gestational age at birth (adjusted B: -0.008 (95%CI: -0.04; 0.02); p = 0.889), birth weight (adjusted B: 4.29 (95%CI: -25; 35); p = 0.889), weight Z-score (adjusted B: -0.01 (95%CI: -0.03; 1); p = 0.336), 5' Apgar scores (adjusted B: -0. -9.8e
CONCLUSIONS
CONCLUSIONS
The estimated maternal nasopharyngeal viral load in pregnant women affected by COVID-19 during the third trimester is not associated with main perinatal outcomes.
Identifiants
pubmed: 36878392
pii: S2468-7847(23)00036-3
doi: 10.1016/j.jogoh.2023.102569
pmc: PMC9985537
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102569Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Références
Lancet Child Adolesc Health. 2020 Apr;4(4):e8
pubmed: 32151320
Clin Infect Dis. 2022 Aug 24;75(1):e715-e725
pubmed: 34922338
Nat Commun. 2020 Jul 14;11(1):3572
pubmed: 32665677
JAMA. 2020 Jun 2;323(21):2198-2200
pubmed: 32352491
Signal Transduct Target Ther. 2021 Jul 7;6(1):255
pubmed: 34234112
Am J Obstet Gynecol. 2021 Jan;224(1):35-53.e3
pubmed: 32739398
Am J Reprod Immunol. 2018 Nov;80(5):e13049
pubmed: 30225853
Am J Obstet Gynecol. 2000 Dec;183(6):1537-43
pubmed: 11120524
Lancet Digit Health. 2022 Feb;4(2):e95-e104
pubmed: 35034863
Prostaglandins Leukot Essent Fatty Acids. 2004 Feb;70(2):87-100
pubmed: 14683686
Immun Inflamm Dis. 2022 Mar;10(3):e580
pubmed: 34904379
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34196300
Lancet Glob Health. 2021 Jun;9(6):e759-e772
pubmed: 33811827
JCI Insight. 2021 Oct 8;6(19):
pubmed: 34622802
J Clin Invest. 2021 Oct 1;131(19):
pubmed: 34428181
J Infect Public Health. 2021 Jul;14(7):863-875
pubmed: 34118736
Nat Commun. 2020 Oct 15;11(1):5164
pubmed: 33060565
Am J Obstet Gynecol. 2020 Nov;223(5):764-768
pubmed: 32730899
JAMA. 2020 Jul 10;:
pubmed: 32648892
Nat Commun. 2020 Oct 30;11(1):5493
pubmed: 33127906
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Sci Rep. 2021 Mar 30;11(1):7163
pubmed: 33785784
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Emerg Infect Dis. 2021 Oct;27(10):2535-2543
pubmed: 34352196
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
Eur J Pediatr. 2022 Apr;181(4):1385-1393
pubmed: 35088115
J Clin Virol. 2020 Jun;127:104384
pubmed: 32361285
AJOG Glob Rep. 2022 Feb;2(1):100049
pubmed: 35005663
Vaccines (Basel). 2021 Apr 15;9(4):
pubmed: 33921113
J Clin Pharmacol. 2012 May;52(5):729-37
pubmed: 21602519